WEINBERGEROVÁ, Barbora, M. ČERŇAN, Tomáš SZOTKOWSKI, Lukáš SEMERÁD, T. KABUT, J. NAVRÁTILOVÁ, N. PODSTAVKOVÁ, Jiřina PROCHÁZKOVÁ, Ivana JEŽÍŠKOVÁ, Iveta KLEMEŠOVÁ, A. FOLTA and Jiří MAYER. Gemtuzumab ozogamicin s Midostaurinem v intenzivní léčbě CD33/FLT3+ AML – aktualizovaná data. (Gemtuzumab ozogamicin with Midostaurin in the intensive treatment of CD33/FLT3+ AML - updated data). In XXXV. Olomoucké hematologické dny in Transfuze a Hematologie Dnes. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Gemtuzumab ozogamicin s Midostaurinem v intenzivní léčbě CD33/FLT3+ AML – aktualizovaná data.
Name (in English) Gemtuzumab ozogamicin with Midostaurin in the intensive treatment of CD33/FLT3+ AML - updated data
Authors WEINBERGEROVÁ, Barbora (203 Czech Republic, belonging to the institution), M. ČERŇAN (203 Czech Republic), Tomáš SZOTKOWSKI (203 Czech Republic), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), T. KABUT (203 Czech Republic), J. NAVRÁTILOVÁ (203 Czech Republic), N. PODSTAVKOVÁ (203 Czech Republic), Jiřina PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), Iveta KLEMEŠOVÁ (203 Czech Republic), A. FOLTA (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition XXXV. Olomoucké hematologické dny in Transfuze a Hematologie Dnes, 2023.
Other information
Original language Czech
Type of outcome Conference abstract
Field of Study 30205 Hematology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/23:00131059
Organization unit Faculty of Medicine
Keywords in English Gemtuzumab ozogamicin; Midostaurin; AML
Tags rivok
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 13/3/2024 08:54.
Abstract
Gemtuzumab ozogamicin s Midostaurinem v intenzivní léčbě CD33/FLT3+ AML – aktualizovaná data - konferenční abstrakt.
Abstract (in English)
Gemtuzumab ozogamicin with Midostaurin in the intensive treatment of CD33/FLT3+ AML - updated data - conference abstract.
Links
LX22NPO5102, research and development projectName: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)
Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES
PrintDisplayed: 24/7/2024 16:34